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Breast-Cancer Predisposition in Multiple Endocrine Neoplasia 
Type 1
To the Editor: Multiple endocrine neoplasia 
type 1 (MEN1) is caused by germline mutations 
in the MEN1 tumor-suppressor gene and is typi-
cally characterized by parathyroid adenomas, 
duodenopancreatic neuroendocrine tumors, and 
pituitary adenomas.1 Recent studies in animals2 
suggest that MEN1 is involved in breast-cancer 
initiation. Through its encoding of menin, a co-
regulator of estrogen receptor α, MEN1 has been 
implicated in breast-cancer progression.3,4 
To clarify the role of MEN1 in human breast 
cancer, the International Breast Cancer in MEN1 
Study Group assessed the incidence of breast 
cancer in the Dutch longitudinal MEN1 data-
base, which includes more than 90% of Dutch 
patients with MEN1.5 (Study group members are 
listed in the Supplementary Appendix, available 
with the full text of this letter at NEJM.org.) In 
190 female patients with MEN1, the relative risk 
of invasive breast cancer was 2.83 (P<0.001), 
with a standardized incidence ratio of 2.14 (95% 
confidence interval [CI], 1.18 to 3.86) (Table S1 
in the Supplementary Appendix). The mean (±SD) 
age at diagnosis of mostly luminal-type breast 
cancer was 48.0±8.8 years, as compared with an 
age of 60 to 65 years in the general population. 
Three of the 12 Dutch breast-cancer patients 
with MEN1 had a history of hyperprolactinemia. 
Risk ratios for other major cancers were not ele-
vated (Table S1 in the Supplementary Appendix).
We validated the observations in three inde-
pendent cohorts from the United States, Tasma-
nia, and France that included a total of 675 fe-
male patients with MEN1. In a comparison of 
breast-cancer prevalence and incidence with cor-
responding data from the respective national 
cancer registries, the risk ratios were 2.40 in the 
United States (P = 0.11), 2.31 in Tasmania (P = 0.22), 
and 2.33 in France (P = 0.03). (The comparisons 
were not significant in the United States and 
Tasmania because of the small numbers of pa-
tients in these cohorts.) The standardized inci-
dence ratio in the combined verification cohorts 
was 1.96 (95% CI, 1.33 to 2.88), and the average 
age at diagnosis was 51 years.
Nuclear localization of menin was reduced by 
more than 50% in 8 of 10 breast-cancer samples 
obtained from Dutch patients with MEN1 on 
immunohistochemical staining with the use of 
menin antibody A300-105A (Bethyl Laboratories) 
(Table 1). Subsequent analysis on DNA sequenc-
ing or multiplex ligation-dependent probe ampli-
fication revealed loss of heterozygosity at the 
MEN1 locus in 3 of 9 tumors. Reduced menin 
Table 1. Characteristics of 10 Patients with Confirmed MEN1 Germline Mutations and Breast Cancer.*
Patient 
No.
Age at 
 Diagnosis
Histologic  
Analysis
Tumor–Node–
Metastasis 
(TNM) Stage
Estrogen 
Receptor
Progesterone 
Receptor HER2
Menin  
Expression
Loss of  
Heterozygosity 
at MEN1 Locus
yr
1 55 Ductal T1N1M0 + − − − −
2 38 Ductal T3N1M0 + + + − −
3 44 Ductal T1N0M0 − − − + −
4 61 Ductal T1N1M0 + − − − −
5 52 Lobular T1N0M0 + + + − −
6 53 Ductal T1N0M0 + + − − +
7 45 Micropapillary T1N1M0 + − − − +
8 42 Ductal† T1N0M0 − + − − +
9 33 Ductal T1N1M0 + + + + −
10 46 Ductal T1N0M0 + + − − ND
* A plus sign indicates positivity, and a minus sign negativity. HER2 denotes human epidermal growth factor receptor 2, 
and ND not determined.
† This patient had a tumor in each breast.
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staining was found in only 4 of 88 control breast 
tumors on a tissue microarray (P<0.001 by Pear-
son’s chi-square test). All studies were conduct-
ed in accordance with regulations of the local 
institutional review board. 
In conclusion, female patients with MEN1 are 
at increased risk for breast cancer. Loss of menin 
expression and loss of heterozygosity at the MEN1 
locus in a subgroup of patients suggest a mam-
mary-cell autonomous effect in MEN1-related 
breast cancer. Our observations indicate that 
MEN1 mutations are involved in human breast 
carcinogenesis. Further research will clarify the 
relevance of MEN1 function for patients with 
nonfamilial breast cancer. Intensified breast-
cancer screening at a relatively young age should 
be considered in female patients with MEN1.
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corrections
Ledipasvir and Sofosbuvir for Previously Treated HCV Geno-
type 1 Infection (April 17, 2014;370:1483-93). In the fourth 
paragraph of the Discussion (page 1491), the first sentence 
should have ended, “. . . the rates of response were similar in 
patients with cirrhosis (100% with both regimens) and those 
without cirrhosis (99% with both regimens),” rather than 
“. . . patients with cirrhosis (99% with both regimens) and 
those without cirrhosis (100% with both regimens).” The arti-
cle is correct at NEJM.org.
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheim-
er’s Disease (January 23, 2014;370:311-21). In Results, in the 
Biologic Markers and Neuroimaging Outcomes subsection, the 
final sentence of the penultimate paragraph (page 318) should 
have begun, “Whole-brain volume decreased slightly in the so-
lanezumab group and the placebo group . . . ,” rather than 
“Whole-brain volume increased slightly . . . .” The article is 
correct at NEJM.org.
Upper-Airway Stimulation for Obstructive Sleep Apnea (Janu-
ary 9, 2014;370:139-49). In the list of authors (page 139), Dr. 
Vanderveken’s first name should have been “Olivier,” rather 
than “Oliver.” The article is correct at NEJM.org.
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